
SyntheticGestalt has announced today that it has entered into a research agreement with Tokyo Institute of Technology (Address: Meguro, Tokyo President: Kazuya Masu; hereafter "Tokyo Tech") to pursue novel enzyme candidates for CO2 fixation by bacteria.
The project will aim to find better alternatives for one of the key enzymes of microbial CO2 fixation pathway, called the PCC enzyme (Propionyl-CoA carboxylase), which consists of "A" and "B" subunits. SyntheticGestalt will leverage its capability to find novel enzyme candidates without relying on sequence similarity, to find previously unknown and highly efficient PCC "B" alternatives, to drastically improve the process of CO2 fixation in a model organism.
Once SyntheticGestalt produces the list of novel enzyme candidates, Tokyo Tech will conduct experiments to confirm the CO2 fixation activity of the predicted candidate enzymes.
Through this project, SyntheticGestalt and Tokyo Tech hope to establish the groundwork for a future line of bioengineering and biotechnology that are not only industrially valuable, but also contribute to the amelioration of climate change.
SyntheticGestalt is an AI R&D company specializing in the life science field including AI drug discovery. In addition to contributing to humanity through drug discovery, through programmes such as this joint research project, we are advancing R&D on solving SDGs issues related to global environmental issues, such as the realization of a decarbonized society, using our proprietary machine learning models.
